BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Valor Medical Reports Early Clinical Results of New Technology to Treat Cerebral Aneurysms at American Society of Neuroradiology Conference


6/3/2008 10:25:40 AM

NEW ORLEANS, June 2 /PRNewswire/ -- Dr. Charles Kerber, University of California San Diego, reported today at the American Society of Neuroradiology Conference in New Orleans the early results on the use of a new technology, Neucrylate(TM), to treat cerebral aneurysms. Neucrylate is a liquid embolic that has been developed by Valor Medical, a San Diego, CA, medical device company. "The patients have had very positive results and to date the accumulated patient implant times have reached 1400 days," Dr. Kerber stated.

The implant procedure begins by placing a microcatheter into an artery in the groin and then is passed up into the brain. This catheter is positioned in the aneurysm and Neucrylate is injected into the aneurysm. When Neucrylate comes in contact with the blood in the aneurysm it changes from a liquid to a sponge-like material. Once the catheter is in place the treatment time is approximately 1 -2 minutes.

Dr. Sean Pakbaz, University of California San Diego, has performed all the implants to date. "The more I use Neucrylate the more I'm impressed with how it works. Reducing the time it takes to treat an aneurysm is always a major goal when working in the brain. Implanting Neucrylate takes a lot less time than implanting coils. Neucrylate also fills the aneurysm compared to coils which only fill 30-40% of the aneurysm," Dr. Pakbaz stated.

Clark Adams, CEO, said, "Valor Medical is very excited with the early results from our clinical trials. Valor will be expanding the trial sites in Europe within a few months and we expect to begin trials in the U.S. later this year. The company anticipates launching Neucrylate in Europe by early 2010".

http://www.valormedical.com

CONTACT: Clark Adams of Valor Medical, +1-858-643-1675,
cadams@valormedical.com

Web site: http://www.valormedical.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->